CTLA4 and melanoma: However, immunotherapy is currently changing the landscape of melanoma treatment; immunomodulatory therapies, such as anti-PD-1 and anti-CTLA-4 antibody drugs, are the standard of care for patients with metastatic or unresectable melanoma.